About Us
AbBC Therapies is pioneering a new class of targeted biologics that merge the precision of antibody-drug conjugates (ADCs) with the potent apoptotic and immune-activating properties of Granzyme B (GrB). Our proprietary Targeted Granzyme B Immunotherapy (TGI) platform harnesses a fully human, catalytically active GrB molecule—nature’s own cancer-cell killer—fused to tumor-specific antibodies to selectively deliver a powerful cytotoxic payload directly into malignant cells.
Unlike ADCs that depend on chemical linkers and synthetic toxins, our biologic construct offers:
- A cleaner mechanism of action, activating multiple apoptosis pathways directly.
- Improved safety, minimizing off-target toxicity.
- Lower manufacturing cost, driven by a scalable, protein-based process.
- Versatility across tumor types, with potential expansion into ophthalmologic diseases.
With seven differentiated programs advancing through discovery and preclinical development, AbBC Therapies is redefining what targeted therapy can achieve—bridging the precision of ADCs with the curative intent of immunotherapy.